Close menu
  • Home
  • Search
  • Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study.
  • https://doi.org/10.1080/14796694.2025.2567230Copy DOI Icon

Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study.

Show More
aduio-icon
Listen Star icon
aduio-icon
Listen Star icon
  • Abstract
  • Literature Map
  • Similar Papers
Abstract
Translate article icon Translate Article Star icon
Take notes icon Take Notes

Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study.

Save Icon
Up Arrow
Open/Close
  • Ask R Discovery Star icon
  • Chat PDF Star icon

AI summaries and top papers from 250M+ research sources.

Copyright 2026 Cactus Communications. All rights reserved.

Privacy PolicyCookies PolicyTerms of UseCareers